Friday, July 10, 2026

Drug profile · INN

turoctocog alfa

turoctocog alfa (NOVOEIGHT) is a coagulation factor viii exogenous protein.

EMA: approved PMDA: approved Blood and blood forming organs (B02) B02BD02
Patents linked 0
Pipeline programs 2
News articles 0
Drug details — turoctocog alfa
Class
Blood and blood forming organs (B02)
Route
Patents
0
Programs
2
Data quality
0.83

Quick answer

turoctocog alfa (NOVOEIGHT) is a coagulation factor viii exogenous protein.

Key facts

INN turoctocog alfa
Brand NOVOEIGHT
Mechanism Coagulation factor VIII exogenous protein
Target Coagulation factor VIII
Therapeutic class Blood and blood forming organs (B02)
ATC code B02BD02

Mechanism of action

Coagulation factor VIII exogenous protein

Primary target: Coagulation factor VIII

Approval history

Authority Status Date
EMA approved
PMDA approved

Pipeline programs

  1. turoctocog alfa pegol Phase 3 · Novo Nordisk A/S · Congenital Bleeding Disorder
  2. turoctocog alfa Approved · Novo Nordisk A/S · Congenital Bleeding Disorder

Related & competitor drugs

  1. apixaban Blood and blood forming organs (B01)
  2. berotralstat Blood and blood forming organs (B06)
  3. bivalirudin Blood and blood forming organs (B01)
  4. c1 inhibitor (human) Blood and blood forming organs (B06)
  5. clopidogrel Blood and blood forming organs (B01)
  6. dabigatran etexilate Blood and blood forming organs (B01)

Frequently asked questions

What is turoctocog alfa?

turoctocog alfa (NOVOEIGHT) is a coagulation factor viii exogenous protein.

What is the brand name for turoctocog alfa?

NOVOEIGHT is a marketed brand name for turoctocog alfa. Check FDA Drugs@FDA for the current US label holder and prescribing information.